

Phase I Trial: Quotient Code QSC300687

Submission date 28/05/2024	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 31/05/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 21/06/2024	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Nand Singh

Contact details

Mere Way, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

Type(s)

Public, Scientific

Contact name

Ms Kavita Dhamdhare

Contact details

15440 Laguna Canyon Road, Suite 160
Irvine
United States of America
CA 92618

Type(s)

Public, Scientific

Contact name

Ms Alisa Hewitt

Contact details

15440 Laguna Canyon Road, Suite 160
Irvine
United States of America
CA 92618

Additional identifiers

Integrated Research Application System (IRAS)

1008711

Protocol serial number

Quotient Code: QSC300687

Study information

Scientific Title

Phase I Trial: Quotient Code QSC300687

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

submitted 30/04/2024, London - Surrey Borders REC (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; + 44 (0) 20 7104 8057; surreyboundaries.rec@hra.nhs.uk), ref: 24/LO/0231

Study design

Mass balance recovery pharmacokinetic metabolite profiling and identification and safety and tolerability study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

18/01/2025

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

02/07/2024

Date of final enrolment

18/01/2025

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Quotient Sciences Limited

Mere Way, Ruddington

Nottingham

United Kingdom

NG11 6JS

Sponsor information

Organisation

Tarsus Pharmaceuticals, Inc.

Funder(s)

Funder type

Industry

Funder Name

Tarsus Pharmaceuticals, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available